Dr Reddy's Laboratories forays into new terrain to give 'top-5' aim a shot

Analysts think that these new entries may help the company navigate multiple risks in the Indian branded market

With an eye on breaking into the top five players’ list in the domestic pharmaceuticals industry, Dr Reddy’s Laboratories (DRL) is entering new areas — from trade generics to child nutrition.

As part of its Horizon 2 strategy, the next leg of growth will come from cell gene therapy, new chemical entities and immuno-oncology assets, apart from legacy growth drivers like branded generics and biosimilars, among others.

After foraying into trade generics last month, DRL has now entered the child immunity market, which is estimated to be about Rs 1,600 crore in size and growing in double digits.

Analysts think that these new